Krónikus mieloid leukémia (CML): ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• ABL1 12
• TP53 1
• JAK 1
• AKT 0
• IDH 4
• ERK 0
• FLT3 2
• PI3K 0
• JNK 0
• STAT3 0
• BCL-2 2
• CD19 1
• HSP90 0
• KIT 1
• PDGFR 0
• CSF1R 2
• HDAC 0
• HIF-1 0
• IL-1 2
• MAPK 0
• PPAR 0
• AMPK 0
• CD123 0
• CD38 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• mTOR 0
• NLRP3 0
• NRF2 0
• RAS 0
• RUNX1 0
• BTK 0
• CD20 0
• CD22 0
• CD33 0
• CD40 0
• CD47 1
• CTLA-4 0
• CXCR4 0
• G6PD 0
• GLP-1 0
• IL-15 0
• IL-6 1
• KRAS 0
• MEK 1
• MYC 0
• NPM1 0
• NRAS 0
• PD-1 0
• PRMT5 0
• PTEN 0
• SGLT2 0
• SIRT1 0
• TIM-3 0
• YAP 0

30+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon 2020) · ERC-STG

  Functional Interrogation of Non-coding DNA Sequences in leukemia development and drug resistance (FIND-seq)

  St. Anna Kinderkrebsforschung Gmbh· Wien, Ausztria· EU contribution 1 784 000 EUR· until 2027. aug.

  The disease is named only in the funder's project summary, not in the title.

1 of 1 running projects, newest first. Listed amounts together: 1,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

  NCT04216563· M.D. Anderson Cancer Center· Frissítve: 2026. márc. 2.

  “75% \< Participants, Administrativley Complete”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

  NCT03576547· M.D. Anderson Cancer Center· Frissítve: 2025. máj. 8.

  “The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· Novartis Pharmaceuticals· Forrás

• Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

  NCT06427811· Novartis Pharmaceuticals· Forrás

• Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

  NCT06514534· Novartis Pharmaceuticals· Forrás

• Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· Takeda· Forrás

• Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

  NCT04666259· Novartis Pharmaceuticals· Forrás

• Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

  NCT05384587· Novartis Pharmaceuticals· Forrás

• Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response

  NCT02852486· University of Campinas, Brazil· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 2
• Gene Expression Profiling 6
• Sequence Analysis, RNA 2
• Exome Sequencing 1
• Proteomics 5
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 13
• Xenograft Model Antitumor Assays 19
• Magnetic Resonance Imaging 4
• Machine Learning 3
• Cohort Studies 9
• Genome-Wide Association Study 3

• Extramedullary T-Lymphoblastic Blast Crisis in Chronic Myeloid Leukaemia: A Unique Cytologic Diagnosis Confirmed by Flow Cytometry.

  Cytopathology, 2026. szept.

• Peripheral Blood Profiles Reflecting Progenitor Lineage Balance are Associated With Molecular Response in Chronic Myeloid Leukemia.

  Exp Hematol, 2026. aug.

• What is the optimal threshold for aberrant lymphoblasts at diagnosis to predict lymphoid transformation in chronic myeloid leukemia?

  Cytometry B Clin Cytom, 2026. jún.

• Simultaneous chromatographic quantification of upadacitinib, nilotinib, and tryptophan decoding myeloid leukemia and liver cancer integrated with ELISA and Flow cytometry.

  J Chromatogr B Analyt Technol Biomed Life Sci, 2025. dec.

• Chemopreventive Effects of Dietary Eicosapentaenoic Acid Supplementation in Experimental Myeloid Leukemia.

  Cancer Prev Res (Phila), 2015. aug.

• Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.

  Mol Pharm, 2011. ápr.

• Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.

  J Pharmacol Exp Ther, 2010. júl.

• [Reactive oxygen species and mitochondrial membrane potential changes in leukemia cells during 6-gingerol induced apoptosis].

  Zhong Yao Cai, 2010. ápr.

• Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.

  Med Oncol, 2010. márc.

• [Effect of berberine on the differentiation and apoptosis of K562 cell line].

  Zhong Yao Cai, 2009. márc.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.